Interstitial Lung Disease Independently Associated with Higher Risk for COVID-19 Severity and Mortality: A Meta-analysis of Adjusted Effect Estimates

Overview

Journal Int Immunopharmacol

Specialties Allergy & Immunology
Pharmacology

Date 2022 Aug 3

PMID 35921779

Authors

Ying Wang

Yuqing Hao

Mengke Hu

Yadong Wang

Haiyan Yang

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study was to address the association between interstitial lung disease and the risk for severity and mortality among patients with coronavirus disease 2019 (COVID-19).

Methods: The electronic databases of PubMed, Web of Science and EMBASE were systematically searched. The pooled effect size with 95 % confidence interval (CI) was computed by a random-effects meta-analysis model. Heterogeneity test, sensitivity analysis, subgroup analysis, meta-regression analysis, Begg's test and Egger's test were performed.

Results: A total of sixteen eligible studies with 217,260 COVID-19 patients were enrolled in this meta-analysis. The findings based on adjusted effect estimates indicated that pre-existing interstitial lung disease was significantly associated with higher risk for COVID-19 severity (pooled effect = 1.34 [95 % CI: 1.16-1.55]) and mortality (pooled effect = 1.26 [95 % CI: 1.09-1.46]). Consistent results were observed in the subgroup analysis stratified by sample size, age, the percentage of male patients, study design, setting, the methods for adjustment and the factors for adjustment. The results of meta-regression demonstrated that sample size, age and region might be the potential sources of heterogeneity. Sensitivity analysis exhibited that our results were stable and robust. No publication bias was observed in Egger's test and Begg's test.

Conclusion: This meta-analysis on the basis of adjusted effect estimates demonstrated that pre-existing interstitial lung disease was independently associated with significantly higher risk for COVID-19 severity and mortality.

Citing Articles

Trends of mortality from chronic respiratory diseases by sex and ethnicity in the USA: a secular analysis from 1979 to 2021 using data from death certificates.

Meng Y, Han X, Ji Q, Zhang A, Zhan Y, Chen X BMJ Open Respir Res. 2024; 11(1).

PMID: 39581694 PMC: 11590864. DOI: 10.1136/bmjresp-2024-002296.

Significant association between asthma and a lower risk of mortality among COVID-19 patients in Spain: A meta-analysis.

Shi L, Han X, Wang Y, Xu J, Yang H Qatar Med J. 2024; 2024(3):34.

PMID: 39040991 PMC: 11262156. DOI: 10.5339/qmj.2024.34.

Artificial intelligence-based analysis of the spatial distribution of abnormal computed tomography patterns in SARS-CoV-2 pneumonia: association with disease severity.

Kataoka Y, Tanabe N, Shirata M, Hamao N, Oi I, Maetani T Respir Res. 2024; 25(1):24.

PMID: 38200566 PMC: 10777587. DOI: 10.1186/s12931-024-02673-w.

Mortality in patients with interstitial lung diseases hospitalized by severe or critical COVID-19.

Pruneda A, Barreto-Rodriguez J, Selman M, Juarez-Hernandez F, Buendia-Roldan I BMC Pulm Med. 2023; 23(1):388.

PMID: 37828511 PMC: 10571283. DOI: 10.1186/s12890-023-02697-w.

References

DerSimonian R, Laird N . Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015; 45(Pt A):139-45. PMC: 4639420. DOI: 10.1016/j.cct.2015.09.002. View

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009; 6(7):e1000100. PMC: 2707010. DOI: 10.1371/journal.pmed.1000100. View

Matarese A, Gambardella J, Sardu C, Santulli G . miR-98 Regulates TMPRSS2 Expression in Human Endothelial Cells: Key Implications for COVID-19. Biomedicines. 2020; 8(11). PMC: 7693865. DOI: 10.3390/biomedicines8110462. View

Wang Y, Feng R, Xu J, Hou H, Feng H, Yang H . An updated meta-analysis on the association between tuberculosis and COVID-19 severity and mortality. J Med Virol. 2021; 93(10):5682-5686. PMC: 8242817. DOI: 10.1002/jmv.27119. View

Wang Y, Xu J, Wang Y, Hou H, Feng H, Yang H . An updated meta-analysis on the relationship between obesity and COVID-19 mortality. Metabolism. 2021; 122:154820. PMC: 8239205. DOI: 10.1016/j.metabol.2021.154820. View

Esposito A, Menon A, Ghosh A, Putman R, Fredenburgh L, El-Chemaly S . Increased Odds of Death for Patients with Interstitial Lung Disease and COVID-19: A Case-Control Study. Am J Respir Crit Care Med. 2020; 202(12):1710-1713. PMC: 7737588. DOI: 10.1164/rccm.202006-2441LE. View

Castelino F, Varga J . Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther. 2010; 12(4):213. PMC: 2945045. DOI: 10.1186/ar3097. View

Han X, Xu J, Hou H, Yang H, Wang Y . Impact of asthma on COVID-19 mortality in the United States: Evidence based on a meta-analysis. Int Immunopharmacol. 2021; 102:108390. PMC: 8611693. DOI: 10.1016/j.intimp.2021.108390. View

Duchemann B, Annesi-Maesano I, Jacobe de Naurois C, Sanyal S, Brillet P, Brauner M . Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris. Eur Respir J. 2017; 50(2). DOI: 10.1183/13993003.02419-2016. View

10.

Mollalo A, Rivera K, Vahabi N . Spatial statistical analysis of pre-existing mortalities of 20 diseases with COVID-19 mortalities in the continental United States. Sustain Cities Soc. 2021; 67:102738. PMC: 7843116. DOI: 10.1016/j.scs.2021.102738. View

11.

Balduzzi S, Rucker G, Schwarzer G . How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019; 22(4):153-160. PMC: 10231495. DOI: 10.1136/ebmental-2019-300117. View

12.

Sacks D, Baxter B, Campbell B, Carpenter J, Cognard C, Dippel D . Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke. 2018; 13(6):612-632. DOI: 10.1177/1747493018778713. View

13.

Hou H, Li Y, Zhang P, Wu J, Shi L, Xu J . Smoking Is Independently Associated With an Increased Risk for COVID-19 Mortality: A Systematic Review and Meta-analysis Based on Adjusted Effect Estimates. Nicotine Tob Res. 2021; 23(11):1947-1951. PMC: 8244809. DOI: 10.1093/ntr/ntab112. View

14.

Ouyang L, Gong J, Yu M . Pre-existing interstitial lung disease in patients with coronavirus disease 2019: A meta-analysis. Int Immunopharmacol. 2021; 100:108145. PMC: 8450148. DOI: 10.1016/j.intimp.2021.108145. View

15.

Xu J, Xiao W, Shi L, Wang Y, Yang H . Is Cancer an Independent Risk Factor for Fatal Outcomes of Coronavirus Disease 2019 Patients?. Arch Med Res. 2021; 52(7):755-760. PMC: 8142843. DOI: 10.1016/j.arcmed.2021.05.003. View

16.

Kaur S, Tripathi D, Yadav A . The Enigma of Endothelium in COVID-19. Front Physiol. 2020; 11:989. PMC: 7417426. DOI: 10.3389/fphys.2020.00989. View

17.

Kato S, Inui N, Hakamata A, Suzuki Y, Enomoto N, Fujisawa T . Changes in pulmonary endothelial cell properties during bleomycin-induced pulmonary fibrosis. Respir Res. 2018; 19(1):127. PMC: 6019800. DOI: 10.1186/s12931-018-0831-y. View

18.

Shields A, Anantharachagan A, Arumugakani G, Baker K, Bahal S, Baxendale H . Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK. Clin Exp Immunol. 2022; 209(3):247-258. PMC: 8807296. DOI: 10.1093/cei/uxac008. View

19.

Drake T, Docherty A, Harrison E, Quint J, Adamali H, Agnew S . Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. Am J Respir Crit Care Med. 2020; 202(12):1656-1665. PMC: 7737581. DOI: 10.1164/rccm.202007-2794OC. View

20.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View